Karuna Therapeutics stock: Bristol Myers Squibb acquisition reshapes biotech landscape for US investors

Karuna Therapeutics (ISIN: US5011311096) was acquired by Bristol Myers Squibb in 2024 for $14 billion, marking a pivotal moment in schizophrenia treatment innovation. US investors should watch for integration progress and pipeline advancements as of March 2026. The deal highlights ongoing M&A activity in biotech.

Karuna Therapeutics stock no longer trades independently following its acquisition by Bristol Myers Squibb in March 2024. The $14 billion deal, one of the largest biotech buyouts in recent years, centered on Karuna's lead drug KarXT, a potential blockbuster for schizophrenia. US investors should pay attention now because BMS is advancing KarXT toward launch, with FDA approval secured in September 2024 and commercialization ramping up in 2025-2026 amid high unmet needs in mental health treatments.

As of: 23.03.2026

Dr. Elena Voss, Biotech Market Analyst at Global Health Investments: Tracking Karuna's integration into BMS reveals key catalysts for schizophrenia therapy innovation and investor returns in neurology-focused portfolios.

Background of the Acquisition

Karuna Therapeutics developed KarXT, a novel muscarinic agonist targeting schizophrenia without dopamine blockade, addressing side effects of traditional antipsychotics. Bristol Myers Squibb acquired the company to bolster its neuroscience portfolio, paying $330 per share in cash. The transaction closed swiftly, delisting Karuna from Nasdaq under ticker KRTX.

This move came amid a wave of biotech M&A as larger pharma firms sought innovative assets amid patent cliffs. For Karuna, the deal validated years of research into GPCR-targeted therapies. US investors benefited from a substantial premium, with shares surging over 50% on announcement.

Post-acquisition, Karuna's team integrated into BMS, focusing on KarXT's global rollout. Recent updates confirm manufacturing scale-up and partnerships for distribution. The strategy emphasizes US market penetration first, given high schizophrenia prevalence.

KarXT's Clinical and Regulatory Progress

KarXT, or xanomeline-trospium, succeeded in Phase 3 trials, showing significant symptom reduction with fewer metabolic side effects. FDA approval in late 2024 enabled US launch in early 2025. By March 2026, BMS reports positive early sales data, positioning it as a first-in-class therapy.

Schizophrenia affects over 20 million people globally, with US cases exceeding 3 million. Current treatments often fail due to tolerability issues. KarXT's mechanism offers a differentiated profile, potentially capturing substantial market share estimated at $10 billion annually.

BMS is investing in Phase 3 trials for additional indications like Alzheimer's psychosis and bipolar disorder. Success here could extend patent life and revenue streams. Investors monitor trial readouts expected mid-2026 for upside potential.

Why US Investors Should Care Now

With Karuna folded into BMS (NYSE: BMY), US investors gain indirect exposure through BMY shares. BMY stock has seen volatility, but KarXT contributes to growth projections. Analysts project peak sales over $5 billion, supporting BMY's valuation.

Current market dynamics favor neurology assets as mental health awareness rises post-pandemic. US payer negotiations and reimbursement pathways are progressing favorably. Investors eye quarterly earnings for KarXT uptake metrics.

For German-speaking investors in Germany, Austria, and Switzerland, BMY offers a liquid US-listed vehicle with ADRs available on European exchanges. Portfolio diversification into biotech via established pharma reduces single-stock risk.

Pipeline and Strategic Integration

BMS leverages Karuna's platform for muscarinic modulators beyond KarXT. Early-stage programs target adjunct therapies for depression and ADHD. Integration has accelerated development timelines through BMS resources.

Manufacturing partnerships ensure supply chain resilience. Global rights exclude certain regions, but US focus drives initial value. Strategic fit enhances BMS neuroscience ranking among peers like Eli Lilly and Johnson & Johnson.

Recent executive updates from BMS highlight KarXT as a cornerstone for 2026-2030 revenue. Cross-trial synergies with BMS immunology assets open combination therapy opportunities.

Risks and Open Questions

Commercial risks include physician adoption hurdles for novel mechanisms. Competition from generics and new entrants like long-acting injectables pressures market share. Long-term safety data remains under scrutiny.

Patent challenges could emerge, though composition-of-matter protection extends to 2037. Regulatory hurdles in ex-US markets delay global expansion. Macro factors like US healthcare policy shifts impact reimbursement.

Integration risks involve retaining Karuna talent. Economic downturns could slow uptake in elective psychiatry spending. Investors weigh these against blockbuster potential.

Market Context and Peer Comparison

Biotech M&A remains active, with schizophrenia therapies in demand. Peers like Sage Therapeutics face hurdles, underscoring KarXT's edge. BMS stock trades at a discount to peers on forward P/E, appealing for value investors.

US mental health spending surges, with schizophrenia costs exceeding $50 billion yearly. KarXT addresses adherence issues driving 50% relapse rates. Long-term, digital therapeutics complement pharmacotherapy.

For European investors, US biotech exposure via BMY hedges eurozone pharma slowdowns. Currency dynamics favor USD assets amid ECB policy divergence.

Outlook for Investors

Monitor BMS Q1 2026 earnings for KarXT sales trajectory. Positive readouts from expansion trials could catalyze BMY upside. Risks balanced by diversified BMS portfolio mitigate downside.

Strategic positioning in high-growth neurology positions former Karuna assets for sustained value. US investors prioritize execution milestones over near-term volatility.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.